Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax®) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013–2015

Published 2015 View Full Article

Authors

Keywords

Adverse event, Cell culture, Surveillance, Trivalent inactivated influenza vaccine, Vaccine safety

Journal

VACCINE

Volume 33, Issue 48, Pages 6684-6688

Publisher

Elsevier BV

Online

2015-10-28

DOI

10.1016/j.vaccine.2015.10.084

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started